LUNAR Study (Novocure)
Pivotal, randomized, open-label study of Tumor Treating Fields concurrent with standard of care therapies for treatment of stage 4 non-small cell (NSCLC) following platinum failure.
To test the efficacy and safety of TTFields (device), using the NovoTTF-100L System, concurrent with standard therapies for stage 4 or metastatic lung cancer patients, following progression while on or after platinum based treatment. Tumor Treating Field (TTFields) are a novel non-invasive anti-cancer treatment modality that utilizes low-intensity, alternating electric fields to interfere with processes of cell division. TTFields may inhibit or slow down tumor growth and is FDA approved for the treatment of glioblastoma, an aggressive brain tumor. A portable, light-weight battery operated device will deliver the TTfields to the lung cancer.
Tina Fortney, RN, BSN, CCRC: 425.688.5407, Tina.Fortney@overlakehospital.org
Pooja Rajeevan, CRC: 425.635.6081, Pooja.Rajeevan@overlakehospital.org
Clinical Trial Categories